Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

53.51 -0.84 (-1.55%)
Streaming Delayed Price Updated: 1:13 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apogee Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Apogee Highlights Corporate Progress and Reports Second Quarter 2023 Financial Results
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics Appoints Mark C. McKenna, Healthcare Veteran and Former Chairman, President and CEO of Prometheus Biosciences, as Chairman of its Board
From Apogee Therapeutics, LLC
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2023
 
Via Benzinga
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 Trial of APG777, its Novel Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Apogee Therapeutics, LLC
Via GlobeNewswire
Apogee, Sagimet Debut This Week In First Big IPOs Of Summer
Sagimet and Apogee both made their trading debuts this week, raising cash for their clinical trials after upsizing their respective IPOs. Inflammation and immunology biotech Apogee had the larger of... 
Via Talk Markets
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.